Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer reports ‘landmark’ Betaferon study

Bayer reports ‘landmark’ Betaferon study

6th August 2007

Bayer has reported the publication of a landmark study in the Lancet journal assessing the efficacy of Betaferon (interferon beta-1b) as a treatment for patients showing their first clinical multiple sclerosis event.

According to the trial results, patients administered with the compound exhibited a significant delay in the progression of their disability, with individuals receiving Betaferon showing a 40 per cent lower risk of developing a confirmed disability compared to patients whose treatment was delayed.

The Benefit study involved 468 patients and was conducted at 98 sites in 20 countries worldwide.

Darlene Jody, senior vice-president and president of specialised therapeutics global business at Bayer HealthCare, commented that the firm had radically transformed the treatment of multiple sclerosis with the original launch of Betaferon as a treatment that modified the disease itself.

“The Benefit results have the potential to again transform the MS treatment paradigm as they provide convincing evidence that treating patients with Betaferon shortly after the first clinical event suggestive of MS can delay disability progression,” she added.

In April 2007, Bayer Schering Pharma announced the publication of Betaferon study results relating to the treatment of over 6,000 patients.

The company reported that the presence of neutralising antibodies in patients does not always indicated clinical response to therapy with the compound, with the firm reiterating the importance of basing treatment decisions on the circumstances for each individual.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.